REG - Physiomics PLC - Notice of Interim Results & Investor Presentation

PhysiomicsAnnouncement

02/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220302:nRSB2645Da&default-theme=true

RNS Number : 2645D  Physiomics PLC  02 March 2022

2 March 2022

Physiomics plc

("Physiomics" or "the Company")

 

Notice of Interim Results and Investor Presentation

 

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions, will issue its interim results for the six months ended 31
December 2021 on Monday 7 March 2022.

The Company is further pleased to announce that Dr Jim Millen will provide a
live presentation relating to its interim results via the Investor Meet
Company platform on Tuesday 8 March 2022 at 2:00pm GMT. The presentation is
open to all existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 9:00am the day
before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and "add to meet"
PHYSIOMICS PLC via the following link:
https://www.investormeetcompany.com/physiomics-plc/register-investor
(https://www.investormeetcompany.com/physiomics-plc/register-investor) .
Investors who already follow PHYSIOMICS PLC on the Investor Meet Company
platform will automatically be invited.

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0)20 3764 2341

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of
the European Union (Withdrawal) Act 2018, as amended.

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has
worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle
Therapeutics.

For more information please visit:

 

www.physiomics.co.uk (http://www.physiomics.co.uk)

www.twitter.com/Physiomics (http://www.twitter.com/Physiomics)

www.linkedin.com/company/physiomics-plc/
(http://www.linkedin.com/company/physiomics-plc/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORSSMFMFEESEED